UPDATE - UBS Initiates Coverage on Ardea Biosciences (RDEA) with a Buy; Lesinurad Knocks Out Gout
Go back to UPDATE - UBS Initiates Coverage on Ardea Biosciences (RDEA) with a Buy; Lesinurad Knocks Out Gout| Abbott Laboratories (NYSE: ABT) | Delayed: 114.14 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $114.14 | 52 Week High | $46.38 | |||
| Open | $114.14 | 52 Week Low | $36.00 | |||
| Day High | $114.14 | P/E | 76.09 | |||
| Day Low | $114.14 | EPS | $1.50 | |||
| Volume | 3,899 | |||||
| Ardea Biosciences, Inc. (NASDAQ: RDEA) | Delayed: 31.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.96 | 52 Week High | $32.00 | |||
| Open | $0.00 | 52 Week Low | $13.15 | |||
| Day High | $31.96 | P/E | N/A | |||
| Day Low | $31.96 | EPS | $-3.92 | |||
| Volume | 300 | |||||
